H5P.F Hikma Pharmaceuticals PLC

Healthcare Pharmaceuticals Frankfurt Exchange
19.72 EUR
Close of Nov 13, 2026
13.19 21.42
Market cap
EUR 4.08B
P/E
13.0x
P/B
1.79x
ROE
15.5%
Dividend yield
3.79%
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is H5P.F undervalued?

Graham number
Price19.72
Graham value19.38
Premium1.7%

H5P.F trades 1.7% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Hikma Pharmaceuticals PLC fundamental analysis

No fundamental analysis for Hikma Pharmaceuticals PLC yet.

Hikma Pharmaceuticals PLC stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Hikma Pharmaceuticals PLC

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The Hikma Rx segment offers oral, respiratory, and ot…

Full company profile